Common Vitamin D Pill Tied to 13% Boost in Early Dementia

Imagine a simple, inexpensive pill nudging scores on a cognitive test upward. It sounds almost too good to be true. Yet a small new study reports just that: people with early signs of cognitive decline who took higher daily doses of vitamin D performed noticeably better on a standard cognitive screen.

Researchers working with patients showing mild cognitive impairment (MCI) and sleep problems—two early red flags for dementia—ran cognitive and sleep assessments on 54 adults aged 50 and older. The battery included the Montreal Cognitive Assessment (MoCA) to measure cognition, plus the Pittsburgh Sleep Quality Index (PSQI) and the Epworth Sleepiness Scale (ESS) for sleep. Participants also reported their vitamin D supplementation habits.

When the team compared supplement use with test scores, one signal stood out. After adjusting for age, sex, BMI, education and the type of vitamin D taken, those reporting a daily intake of 5,000 IU or more scored on average 3.78 points higher on the MoCA—about a 13% jump—than participants who did not take vitamin D supplements.

The most striking finding: daily vitamin D at or above 5,000 IU was associated with a roughly 13% higher MoCA score in this group.

Lower daily doses were linked to slightly better scores too, but those differences didn’t reach statistical significance. The association held whether people took vitamin D2 or vitamin D3, the study notes. Still, the authors are careful: this is an observational study with a small sample. Correlation is not causation. The result is a lead, not a prescription.

Why focus on people with both MCI and sleep disturbance? Sleep problems commonly precede or accompany cognitive decline, and some researchers view that combination as a window of opportunity—an early stage where interventions might still change a person’s trajectory. As sleep scientist Victoria Pak of Emory University tells it: this may be a critical moment when cognitive changes are starting but brain-supporting measures could still help.

The broader literature on vitamin D and brain health has grown in recent years. Studies have suggested links between vitamin D deficiency and higher dementia risk, and laboratory work hints at mechanisms by which vitamin D could influence neuroinflammation and neuronal resilience. But clinical evidence remains mixed. Small human studies, inconsistent dosing, and varying outcome measures have kept the picture fuzzy.

Safety matters. The commonly accepted upper daily limit for vitamin D is around 4,000 IU to avoid risks like hypercalcemia—elevated blood calcium that can cause nausea, weakness and kidney problems. The dose associated with the study’s cognitive difference (5,000+ IU) exceeds that limit, so anyone thinking about changing their regimen should consult a clinician and consider blood testing for 25-hydroxyvitamin D levels before increasing intake.

What happens next? Larger, randomized trials are needed to test whether vitamin D supplementation can causally improve cognition or slow decline in people at risk for dementia. If future research confirms a protective effect, the public health implications would be large: vitamin D is cheap, widely available, and already familiar to many.

For now, the study is a provocative piece of the puzzle rather than a final answer. It nudges scientists toward a hypothesis worth testing in more powerful studies, and it nudges clinicians toward asking about vitamin D status in patients with early cognitive complaints and sleep issues. The possibility that a commonplace supplement might alter the arc of cognitive aging is too compelling to ignore.